加载中
NASDAQHealthcareMedical - Devices
最新数据
US$6.65
−US$0.12 · -1.77%
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
前收盘价
US$6.65
−US$0.12 · -1.77%
盘后
US$6.61
−US$0.04 · -0.60%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
日内区间
当前US$6.65
52周区间
当前US$6.65
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
26
偏贵
情绪
60
多空交织
风险
42
风险偏高
动量
70
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
日内区间
当前US$6.65
52周区间
当前US$6.65
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 191.3万 USD | 270.3万 USD | 273.48万 USD | 320.07万 USD | 583.05万 USD |
| 销货成本 | 223万 USD | 143.7万 USD | 185.8万 USD | 290.23万 USD | 392.54万 USD |
| 毛利 | −31.7万 USD | 126.6万 USD | 87.68万 USD | 29.84万 USD | 190.52万 USD |
| 研究与开发 | 6912万 USD | 5145.1万 USD | 3102.16万 USD | 1759.01万 USD | 999.49万 USD |
| 销售、一般及管理费用 | 2445.7万 USD | — | 1704.57万 USD | 1521.34万 USD | 913.54万 USD |
| 营业费用 | 9357.7万 USD | 7963.8万 USD | 4901.68万 USD | 3141.27万 USD | 1876.57万 USD |
| 利息收入 | 70.9万 USD | — | 42.81万 USD | 21.04万 USD | 6.86万 USD |
| 利息支出 | 7.3万 USD | 8.2万 USD | 6.71万 USD | 64.87万 USD | 103.42万 USD |
| 折旧和摊销 | 166.1万 USD | 150.7万 USD | 115.77万 USD | 77.41万 USD | 64.01万 USD |
| 营业利润 | −9389.4万 USD | −7837.2万 USD | −4814万 USD | −3111.43万 USD | −1686.06万 USD |
| 净利润 | −9414.4万 USD | −7629.1万 USD | −4602.18万 USD | −3056.38万 USD | −1717.11万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$10.00
上涨空间 50.38%报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM1363.7万0.02%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF766.33万0.01%954亿 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO404.54万0.02%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA283.77万0.01%218.24亿 USD0.03%US$32.66-0.40%
State Street SPDR S&P Health Care Equipment ETFXHE200.76万1.15%1.74亿 USD0.35%US$90.87+1.59%
iShares Micro-Cap ETFIWC164.22万0.12%13.17亿 USD0.60%US$181.66-0.73%
Fidelity Enhanced Small Cap ETFFESM104.9万0.02%64.1亿 USD0.28%US$45.24-0.48%
iShares Core S&P Total U.S. Stock Market ETFITOT76.27万0.00%980.88亿 USD0.03%US$169.43-0.14%iShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAState Street SPDR S&P Health Care Equipment ETFXHEiShares Micro-Cap ETFIWCFidelity Enhanced Small Cap ETFFESMiShares Core S&P Total U.S. Stock Market ETFITOTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
